<DOC>
	<DOC>NCT00908674</DOC>
	<brief_summary>Androcur is an antiandrogenic drug, which blocks the action of male sex hormones. Androcur is used for treatment of advanced prostate cancer. This study investigates the effect of Androcur on quality of life of prostate cancer patients who are taking the drug for 12 months</brief_summary>
	<brief_title>Androcur Effects on Quality of Life</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Cyproterone</mesh_term>
	<mesh_term>Cyproterone Acetate</mesh_term>
	<criteria>Histologically confirmed adenocarcinoma of the prostate Inoperable prostate tumor or progradiated after surgery/ irradiation therapy Locally advanced tumor or distant metastases is present Patient not fulfil the recruitment criteria Liver disease; DubinJohnson syndrome; Rotor syndrome; previous or existing liver tumours (in carcinoma of the prostate only if these are not due to metastases); wasting diseases (with the exception of carcinoma of the prostate); depression; previous or existing thromboembolic processes; diabetes with vascular changes; sicklecell anaemia. As regards patients with prostatic carcinoma who have a history of thromboembolic processes and/or an existing sicklecell anaemia, or diabetes with vascular changes, the risk:benefit ratio must be considered carefully in each individual case before the use of Androcur</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
</DOC>